A Phase 3 Trial of Brepocitinib in Dermatomyositis

Puntos clave

• This trial aims to evaluate the efficacy and safety of brepocitinib in patients with dermatomyositis.
• Phase 3 randomized, double-blind trial conducted in patients diagnosed with dermatomyositis.
• Participants were randomly assigned to receive either brepocitinib or placebo.
• Outcomes were measured using specific clinical and biomarker assessments.
• Brepocitinib showed a significant improvement in muscle strength (p=0.005).
• Reduction in skin symptoms was observed with an odds ratio of 2.3 (95% CI, 1.5-3.5, p=0.02).
• Treatment was well tolerated, with adverse events similar to placebo.